The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of US$ 8.25 Billion in 2023 and is expected to accumulate a market value of US$ 21.40 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. The growth of the non-small cell lung carcinoma (NSCLC) market can be attributed to the rising prevalence of NSCLC across the globe due to increasing air pollution and smoking habits amongst people. The market for non-small cell lung carcinoma (NSCLC) registered a CAGR of 7.3% in the historical period 2017 to 2022.
The presence of a strong pipeline for non-small cell lung carcinoma is projected to propel the growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung carcinoma is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.
Report Attribute | Details |
---|---|
Estimated Base Year Value (2021) | US$ 7.5 Billion |
Expected Market Value (2023) | US$ 8.25 Billion |
Anticipated Forecast Value (2033) | US$ 21.4 Billion |
Projected Growth Rate (2023 to 2033) | 10% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for non-small cell lung carcinoma (NSCLC) reflected a value of 7.3% during the historical period, 2018 to 2022.
Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.
According to an article published in September 2020 titled The impact of the COVID-19 pandemic on lung cancer patients, at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visits in April 2020, and 47 cases finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. Thus, the market for non-small cell lung carcinoma (NSCLC) is expected to register a CAGR of 10% in the forecast period 2023 to 2033.
Smoking and tobacco consumption increasing the number of patients suffering from non-small cell lung carcinoma
The American Cancer Society estimates that lung cancer is one of the highest death-causing diseases in the world. Covid-19 significantly affected non-small cell lung cancer-related clinical trials across the world. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of national healthcare bodies and international healthcare systems worldwide.
The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients.
Approvals of Medication for Lung Carcinoma Propelling Market Growth
As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 Billion patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung carcinoma patients resulted in the high demand for treating the patients.
Recent approvals of new drugs are expected to accelerate market growth during the forecast period. For instance, In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the USA. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States of America FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.
Longer Duration for approval of Medication hampering Growth of Market
The expensive nature of research and development of medication to treat patients is derailing the progress of the market. In addition, the financial burden added by the COVID-19 pandemic is playing a key role in hindering the growth of the market. Furthermore, the time taken for approval of drugs along with certain medications not being approved in spite of being in the clinical trial phase for a longer duration is hampering the overall growth of the non-small cell lung carcinoma market.
Launch of new drugs creating Favorable treatment for non-small cell lung carcinoma in North America
North America is expected to maintain its dominance during the forecast period and is one of the most lucrative regions for the NSCLC market. This is due to the presence of a strong pipeline and research activities undertaken by various industry players and academic institutions.
Thus, North America is expected to account for the largest share of all the regions in 2023. This is attributed to the entry of newer drugs, high investment by players, acceptance of costly drugs, and increased government funding for research and development activities. Owing to the aforementioned reasons, North America is expected to possess a 40% market share for the non-cell lung carcinoma market in 2023.
Less stringent regulator framework opening doors for medication development in the Asia Pacific
Asia Pacific is expected to be the second largest contributor in 2023 for the non-small lung cell carcinoma market. This is owing to the presence of less stringent regulatory procedures for approval and a large patient pool. Japan and China are expected to contribute the highest to the Asia Pacific region due to the availability of advanced drugs, a developed economy, and a large patient pool.
Pricing pressure by the governments of European countries is likely to affect the market negatively during the forecast period. For instance, in October 2016, the National Institute for Health and Care Excellence (NICE) disapproved funding for Opdivo, as it did not meet the required cost-to-benefit ratio. Thus, Asia Pacific is expected to possess a 35% market share for the non-small cell lung carcinoma market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 8.25 Billion |
Market Value in 2033 | US$ 21.4 Billion |
Growth Rate | CAGR of 10% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2017 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
From 2018 to 2022, the non-small cell lung carcinoma (NSCLC) market grew at a CAGR of 7.3%
The global non-small cell lung carcinoma (NSCLC) market is expected to grow with a 10% CAGR from 2023 to 2033.
As of 2033, the non-small cell lung carcinoma (NSCLC) market is expected to reach US$ 21.40 Billion
North America is expected to possess 40% market share for non-small cell lung carcinoma (NSCLC) market in North America.
Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.
1. Executive Summary | Non-Small Cell Lung Carcinoma (NSCLC) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Adenocarcinoma
5.3.2. Squamous Cell Carcinoma
5.3.3. Large Cell Carcinoma
5.3.4. Large Cell Neuroendocrine Tumors
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.2.1. Bevacizumab (Avastin)
6.3.2.2. Necitumumab (Portrazza)
6.3.2.3. Ramucirumab (Cyramza)
6.3.3. Immunotherapy
6.3.3.1. Nivolumab (Opdivo)
6.3.3.2. Atezolizumab (Tecentriq)
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Homecare
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia & Pacific
8.3.5. East Asia
8.3.6. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Treatment
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Treatment
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Treatment
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment
11.3.4. By End User
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Australia
12.2.1.6. New Zealand
12.2.1.7. Rest of South Asia & Pacific
12.2.2. By Type
12.2.3. By Treatment
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By Treatment
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment
13.3.4. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Type
14.2.3. By Treatment
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Treatment
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. United States of America
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Type
15.1.2.2. By Treatment
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Type
15.2.2.2. By Treatment
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Type
15.3.2.2. By Treatment
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Type
15.4.2.2. By Treatment
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Type
15.5.2.2. By Treatment
15.5.2.3. By End User
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Type
15.6.2.2. By Treatment
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Type
15.7.2.2. By Treatment
15.7.2.3. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Type
15.8.2.2. By Treatment
15.8.2.3. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Type
15.9.2.2. By Treatment
15.9.2.3. By End User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Type
15.10.2.2. By Treatment
15.10.2.3. By End User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Type
15.11.2.2. By Treatment
15.11.2.3. By End User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Type
15.12.2.2. By Treatment
15.12.2.3. By End User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Type
15.13.2.2. By Treatment
15.13.2.3. By End User
15.14. Australia
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Type
15.14.2.2. By Treatment
15.14.2.3. By End User
15.15. New Zealand
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Type
15.15.2.2. By Treatment
15.15.2.3. By End User
15.16. China
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Type
15.16.2.2. By Treatment
15.16.2.3. By End User
15.17. Japan
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Type
15.17.2.2. By Treatment
15.17.2.3. By End User
15.18. South Korea
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Type
15.18.2.2. By Treatment
15.18.2.3. By End User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Type
15.19.2.2. By Treatment
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Type
15.20.2.2. By Treatment
15.20.2.3. By End User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Type
15.21.2.2. By Treatment
15.21.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By Treatment
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Pfizer Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. AstraZeneca plc
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. F. Hoffmann-La Roche Ltd.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Eli Lilly and Company
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Boehringer Ingelheim GMBH
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Bristol-Myers Squibb Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Merck & Co., Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Celgene Corp.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Sun Pharmaceutical Industries Ltd.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports